Company Profile

Actinium Pharmaceuticals Inc
Profile last edited on: 6/3/2024      CAGE: 8FC27      UEI: T8BLSFLLLKN4

Business Identifier: AWE technology platform: produces ARCs or Antibody Radiation Conjugates, a highly potent and selective form of targeted radiotherapy
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

100 Park Avenue 23rd Floor
New York, NY 10017
Location: Single
Congr. District: 12
County: New York

Public Profile

Specializing in Myeloablation, Hematopoeitic Stem Cell and Bone Marrow Transplant, Biopharmaceuticals and ADC's, Acute Myeloid Leukemia, and Multiple Myeloma, the publicly traded firm Actinium Pharmaceuticals (NYSE: ATNM) is focused on developing innovative targeted radioimmunotherapies for the treatment of advanced cancer. The firmis developing and commercializing therapies for bone marrow transplant (BMT) -- a type of cellular therapy, and for other adoptive cell therapies. The firm's lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly relapsed or refractory acute myeloid leukemia trial for BMT conditioning; and a Phase I study with a CD19 CAR T-cell therapy with memorial sloan kettering cancer center. The company is also developing a multi-disease, multi-target pipeline of clinical-stage antibody radiation-conjugates targeting the antigens CD45 and CD33 for targeted conditioning and as a therapeutic either in combination with other therapeutic modalities or as a single agent for patients with a range of hematologic malignancies, including acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma. Actinium Pharmaceuticals, Inc. has research collaboration with the Japanese firm Astellas Pharma, Inc. to develop targeted radiotherapies using its Antibody Warhead Enabling technology platforms.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Publicly Traded
Stock Info
IP Holdings

Awards Distribution by Agency

Key People / Management

  Sandesh C Seth -- Chairman & CEO

  Eileen Geoghegan -- Associate Director, Strategic Research and Business Development

  Mark B Geyer

  Dale Ludwig -- Chief Scientific & Technology Officer

Company News

There are no news available.